Syros Pharmaceuticals, Inc. is not engaged in any business activities. The Company is actively engaged in the voluntary delisting process. The Company was previously engaged in developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
31/26/31	$0.000400	+300.00%	84,828
28/26/28	$0.000100	-.--%	1,835
27/26/27	$0.000100	-.--%	5,851
26/26/26	$0.000100	-.--%	4,495
25/26/25	$0.000100	-.--%	16,311

Real-time OTC Markets

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - OTC Markets 07:05:17 30/04/2026 pm IST			5-day change	1st Jan Change
0.000200 ^USD	-.--%		+100.00%	-42.86%

24/25/24	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
19/25/19	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI

Market Cap	61.66L 53.09L 49.85L 45.5L 85.48L 59Cr 86.1L 5.91Cr 2.3Cr 30Cr 2.32Cr 2.26Cr 99Cr	P/E 2022	-0.48x	P/E 2023	-1.34x
Enterprise Value	-7.13Cr -6.14Cr -5.76Cr -5.26Cr -9.88Cr -678.27Cr -9.95Cr -68Cr -27Cr -343.94Cr -27Cr -26Cr -1.14TCr	EV / Sales 2022	-4.44x	EV / Sales 2023	12.6x
Free-Float	99.93%	Yield 2022 *	-	Yield 2023	-

24/25/24	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from S&P TMI Index	CI
19/25/19	Syros Pharmaceuticals, Inc.(OTCPK:SYRS) dropped from NASDAQ Composite Index	CI
01/25/01	Syros Pharmaceuticals to Delist from Nasdaq, Deregister Common Shares	MT
01/25/01	Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025	CI
01/25/01	Syros Pharmaceuticals, Inc. Announces Management Changes	CI
23/24/23	Syros Pharmaceuticals, Inc.(NasdaqGS:SYRS) dropped from S&P Global BMI Index	CI
13/24/13	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/24/13	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/24/13	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/24/13	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
13/24/13	Syros Pharmaceuticals, Inc. Announces Event of Default Occurred Under the Loan and Security Agreement with Oxford Finance LLC	CI
13/24/13	Syros Pharmaceuticals Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	CI
31/24/31	Syros Pharmaceuticals, Inc., Q3 2024 Earnings Call, Oct 31, 2024

13/24/13	Brookline Capital Downgrades Syros Pharmaceuticals to Hold	MT
13/24/13	TD Cowen Downgrades Syros Pharmaceuticals to Hold	MT
13/24/13	JMP Securities Downgrades Syros Pharmaceuticals to Market Perform	MT
13/24/13	HC Wainwright Downgrades Syros Pharmaceuticals to Neutral, $1 Price Target	MT
11/23/11	JMP Securities Adjusts Price Target on Syros Pharmaceuticals to $15 From $16, Maintains Market Outperform Rating	MT

Syros Pharmaceuticals, Inc. Share Price

Stocks

SYRS

US87184Q2066

Biotechnology & Medical Research

Valuation : Syros Pharmaceuticals, Inc.

Chart: Syros Pharmaceuticals, Inc.

Latest news : Syros Pharmaceuticals, Inc.

Analysts' recommendations : Syros Pharmaceuticals, Inc.

Press Releases : Syros Pharmaceuticals, Inc.

News in other languages : Syros Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Syros Pharmaceuticals, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

01/25/01	Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration	BU
18/24/18	Syros Pharmaceuticals : Management Change/Compensation Form 8 K	PU
13/24/13	Syros Pharmaceuticals : Announces Topline Data from SELECT MDS 1 Phase 3 Trial of Tamibarotene in Higher Risk Myelodysplastic Syndrome with RARA Gene Overexpression Form 8 K	PU
13/24/13	Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression	BU
01/24/01	Syros Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides a Business Update	AQ

24/23/24	USA-Les valeurs à suivre à Wall Street (actualisé)
05/21/05	Bourse Zurich: le SMI termine dans le vert juste sous les 12'200 points
05/21/05	Roche signe un accord de livraison avec Syros Pharmaceuticals

1 week	+100.00%
Current month	+100.00%
1 month	+100.00%
Current year	-42.86%

Manager	Title	Age	Since
Gerald Quirk CEO	Chief Executive Officer	58	22/11/2024
Karen Hunady IRC	Investor Relations Contact	-	01/10/2022
Matthew Foster PRN	Corporate Officer/Principal	-	01/03/2025

Date	Insider	Type	Main position	Quantity	% Market Cap.
02/12/24	Nancy Simonian	Sell	Chief Executive Officer	37,070	0.1382%
25/11/24	Nancy Simonian	Sell	Chief Executive Officer	1,34,713	0.5025%
19/11/24	Gerald Quirk	Sell	Chief Financial Officer	46,657	0.1740%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYROS PHARMACEUTICALS, INC.	-.--%	+100.00%	-90.00%	-99.99%	10.73T
LONZA GROUP AG	-0.19%	-1.91%	+0.98%	+17.94%	4.98TCr
REVOLUTION MEDICINES, INC.	-1.11%	-2.84%	+420.04%	+505.15%	4.41TCr
IQVIA HOLDINGS INC.	-0.21%	+0.37%	+36.88%	+17.32%	4.3TCr
BEONE MEDICINES AG	-1.95%	-3.33%	+8.29%	+73.25%	4.09TCr
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	3.31TCr
MEDPACE HOLDINGS, INC.	-1.11%	-4.20%	+25.49%	+119.78%	1.66TCr
ASCENDIS PHARMA A/S	+6.10%	+4.40%	-	-	1.73TCr
EUROFINS SCIENTIFIC SE	+0.17%	-1.86%	+11.88%	+28.35%	1.46TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.12%	-3.46%	+76.50%	+39.37%	1.38TCr
Average	-0.03%	-1.23%	+56.49%	+83.11%	2.73TCr
Weighted average by Cap.	-0.38%	-1.50%	+88.88%	+122.68%

	2022	2023
Net sales	1.49Cr 1.28Cr 1.2Cr 1.1Cr 2.06Cr 141.58Cr 2.08Cr 14Cr 5.55Cr 72Cr 5.59Cr 5.47Cr 237.72Cr	99.36L 85.55L 80.33L 73.33L 1.38Cr 95Cr 1.39Cr 9.52Cr 3.7Cr 48Cr 3.73Cr 3.65Cr 158.73Cr
Net income	-9.47Cr -8.15Cr -7.65Cr -6.99Cr -13Cr -900.62Cr -13Cr -91Cr -35Cr -456.69Cr -36Cr -35Cr -1.51TCr	-16Cr -14Cr -13Cr -12Cr -23Cr -1.57TCr -23Cr -157.66Cr -61Cr -794.05Cr -62Cr -60Cr -2.63TCr
Net Debt	-14Cr -12Cr -11Cr -10Cr -19Cr -1.32TCr -19Cr -132.9Cr -52Cr -669.37Cr -52Cr -51Cr -2.22TCr	-7.75Cr -6.67Cr -6.26Cr -5.72Cr -11Cr -736.94Cr -11Cr -74Cr -29Cr -373.69Cr -29Cr -28Cr -1.24TCr

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.02
3 years	0		8.17
5 years	0		56.4
10 years	0		243.75